Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buchholzia coriacea is a medicinal plant native to West and Central Africa, traditionally used for treating diabetes, infections, inflammation, gastrointestinal disorders, rheumatism, fever, cough, malaria, sleeping sickness, and cancer-related diseases[1][2][3][4]. Its bioactive extracts (notably methanol and ethanol seed/leaf extracts) have demonstrated diverse pharmacological activities including antimicrobial, cytotoxic (anticancer), hypoglycemic, antihypercholesterolemic, anthelmintic, immunomodulatory, antioxidant, neuroprotective, antitrypanosomal, antiplasmodial, and anti-inflammatory effects[1][2][3][4][5]. Active compounds isolated include novel and known alkaloids, flavonoids, saponins, and others. Documented mechanisms include inhibition of pathogen growth (bacterial, fungal, parasitic), cytotoxicity to cancer cell lines, modulation of oxidative stress pathways, nitric oxide modulation, and immunostimulation[1][2][3][4][5]. Toxicity studies in animals up to 5000 mg/kg have found no mortality or notable toxicity, suggesting a wide safety margin[4][5]. There is no evidence of clinical drug formulations or approvals for these indications; research remains primarily preclinical and ethnopharmacological.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on buchholzia coriacea.